Shanghai Fosun Pharmaceutical (Group) Co (2196) Stock Statistics & Valuation Metrics

Shanghai Fosun Pharmaceutical (Group) Co has a market cap or net worth of HKD 65.95B. The enterprise value is HKD 78.25B.

Market Cap

HKD 65.95B

Enterprise Value

HKD 78.25B

Shanghai Fosun Pharmaceutical (Group) Co has 551,940,500 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

551,940,500

Owned by Insiders

―

Owned by Institutions

7.51%

Shanghai Fosun Pharmaceutical (Group) Co’s return on equity (ROE) is 0.07 and return on invested capital (ROIC) is 2.00%.

Return on Equity (ROE)

0.07

Return on Assets (ROA)

0.03

Return on Invested Capital (ROIC)

2.00%

Return on Capital Employed (ROCE)

0.03

Revenue Per Employee

995.60K

Profits Per Employee

80.86K

Employee Count

40,603

Asset Turnover

0.34

Inventory Turnover

3.24

The current PE Ratio of Shanghai Fosun Pharmaceutical (Group) Co is 16.94. Shanghai Fosun Pharmaceutical (Group) Co’s PEG ratio is 2.33.

PE Ratio

16.94

PS Ratio

1.41

PB Ratio

1.18

Price to FCF

162.20

Price to Operating Cash Flow

10.05

PEG Ratio

2.33

In the last 12 months, Shanghai Fosun Pharmaceutical (Group) Co had revenue of 40.42B and earned 3.28B in profits. Earnings per share was 1.24.

Revenue

40.42B

Gross Profit

20.16B

Operating Income

2.54B

Pretax Income

4.98B

Net Income

3.28B

EBITDA

6.05B

Earnings Per Share (EPS)

1.24

In the last 12 months, operating cash flow was 5.26B and capital expenditures -5.55B, giving a free cash flow of -287.92M billion.

Operating Cash Flow

5.26B

Free Cash Flow

-287.92M

Free Cash Flow per Share

0.14

Shanghai Fosun Pharmaceutical (Group) Co pays an annual dividend of HKD 0.45, resulting in a dividend yield of 2.72%

Dividend Per Share

HKD 0.45

Dividend Yield

2.72%

Payout Ratio

29.66%

Free Cash Flow Yield

0.62%

Earnings Yield

5.91%

Beta

0.93

52-Week Price Change

-28.21%

50-Day Moving Average

17.21

200-Day Moving Average

17.56

Relative Strength Index (RSI)

44.01

Average Volume (3m)

3.73M

Shanghai Fosun Pharmaceutical (Group) Co upcoming earnings date is Mar 29, 2027, TBA (Not Confirmed).

Last Earnings Date

Oct 27, 2026

Next Earnings Date

Mar 29, 2027

Ex-Dividend Date

Jul 16, 2026

Shanghai Fosun Pharmaceutical (Group) Co as a current ratio of 0.93, with Debt / Equity ratio of 75.23%

Current Ratio

0.93

Quick Ratio

0.76

Debt to Market Cap

0.72

Net Debt to EBITDA

3.89

Interest Coverage Ratio

2.06

In the past 12 months, Shanghai Fosun Pharmaceutical (Group) Co has paid 841.69M in taxes.

Income Tax

841.69M

Effective Tax Rate

0.17

Shanghai Fosun Pharmaceutical (Group) Co EV to EBITDA ratio is 15.97, with an EV/FCF ratio of 238.18.

EV to Sales

2.07

EV to EBITDA

15.97

EV to Free Cash Flow

238.18

EV to Operating Cash Flow

14.93

Shanghai Fosun Pharmaceutical (Group) Co has HKD 15.76B in cash and marketable securities with HKD 33.71B in debt, giving a net cash position of -HKD 17.96B billion.

Cash & Marketable Securities

HKD 15.76B

Total Debt

HKD 33.71B

Net Cash

-HKD 17.96B

Net Cash Per Share

-HKD 32.53

Tangible Book Value Per Share

HKD 12.27

Gross margin is 49.26%, with operating margin of 7.85%, and net profit margin of 8.23%.

Gross Margin

49.26%

Operating Margin

7.85%

Pretax Margin

12.06%

Net Profit Margin

8.23%

EBITDA Margin

12.95%

EBIT Margin

8.51%

The average price target for Shanghai Fosun Pharmaceutical (Group) Co is HKD 31.20, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target

HKD 31.20

Price Target Upside

88.29% Upside

Analyst Consensus

Moderate Buy

Analyst Count

2

Revenue Growth Forecast

9.88%

EPS Growth Forecast

9.30%

Smart Score

4

AI Score

56